1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Major Depressive Disorder-API Insights, 2014

Major Depressive Disorder-API Insights, 2014

  • November 2014
  • -
  • Delve Insight

Summary

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

DelveInsight’s, Major Depressive Disorder -API Insights, 2014 Report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Major Depressive Disorder. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales forecasts data till 2015.

Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global Market therapeutics scenario for Major Depressive Disorder.
- A review of the marketed products under prescription for Major Depressive Disorder, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Major Depressive Disorder with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Major Depressive Disorder drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Major Depressive Disorder drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to Buy
- Evaluate the marketing status and exclusivity details of Major Depressive Disorder key products to exploit opportunities for generic drug development opportunities.
- Key players in the pharmaceutical industry.
-Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Major Depressive Disorder.
- API intelligence over marketed drugs for Major Depressive Disorder and gaining primary intelligence over active ingredients manufacturers across the globe.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Major Depressive Disorder-API Insights, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Discontinued Drugs Information

List of Tables
Major Depressive Disorder Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Major Depressive Disorder Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Major Depressive Disorder Therapeutic Market, US, (Year), 2014
Major Depressive Disorder Marketed Drugs, API Manufacturers by US DMF Status, 2014
Major Depressive Disorder Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Major Depressive Disorder Therapeutic Market, Global Sales (in million USD), 2014
Major Depressive Disorder Marketed Drugs, API Manufacturers, Global, 2014
Discontinued Drugs for Major Depressive Disorder, 2014

List of Figures
Major Depressive Disorder Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Major Depressive Disorder Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Major Depressive Disorder Therapeutic Market, US, (Year), 2014
Major Depressive Disorder Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Major Depressive Disorder Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Major Depressive Disorder Therapeutic Market, Global Sales (in million USD), 2014
Major Depressive Disorder Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

Companies Mentioned
Noven Pharmaceuticals, Inc.
GlaxoSmithKline plc
Eli Lilly and Company
Pfizer Inc.
Forest Laboratories, Inc.
Lilly USA, LLC
Otsuka Pharmaceutical Co., Ltd.
GlaxoSmithKline LLC
Edgemont Pharmaceuticals, LLC
Aurobindo Pharma Ltd
Novartis AG
sanofi-aventis U.S. LLC.
AstraZeneca Pharmaceuticals, LP
Organon USA Inc.
Kedrion S.p.A.
Covis Pharmaceuticals, Inc
Teva Pharmaceutical Industries Limited
Osmotica Pharmaceutical Corp.
Angelini Labopharm
Wockhardt Limited
Rising Pharmaceuticals, Inc
Ranbaxy Pharmaceuticals Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.